Research SARMs Today
Recently, there has been a growing interest in compounds called Selective Androgen Receptor Modulator (s), SARMs.
Although SARMs are categorized differently, they share numerous effects and risks as anabolic steroids . By analyzing questions found on the internet, researchers can address public concerns and develop guidelines for the future of SARMs and devoid of any reference to human use as these are not dietary supplements.
Extensive research is crucial to ensuring the safety of SARMs in the future. Exploring the most popular questions about SARMs can provide valuable insights into this topic; and gaining insight via clinical development programs is needed to expand on SARMs knowledge.
This article will discuss five of the most commonly asked questions about SARMs on Quora and provide an update on the current state of research. Continue reading for further details.
Top Questions About SARMs
SARMs are selective androgen receptor modulators. Their design could replace many steroidal androgens .
They are partial androgen receptor agonists, that could limit systemic reactions. Early research provided insight into muscle mass gains without affecting the prostate in rats. Research continues to show how some of these products can lead to organ damage and raise triglyceride levels .
Quora is a website that allows users to ask and answer questions on various topics. It is a great resource to get public opinions, but research-based evidence must also be explored. Below are science-based evidence related to common questions.
1. Are SARMs Less Harmful for Research Subjects?
Research indicates SARMs may have a potential in the future for their androgen receptor targeting and tissue wasting improvements. They are chemically-engineered compounds and molecules that have various agonist and antagonist effects on androgen receptors .
There is a misconception that SARMs are less harmful than other androgen-therapy compounds such as testosterone. Early studies show promising results that SARMs are more tissue-specific and have fewer androgenic side effects .
Clinical and research studies are also examining their effect on :
- Breast cancer
- Muscle atrophy
- Stress urinary incontinence
- And more
Current research has pointed towards positive results in prostate shrinkage, breast cancer management, and reversing muscle wasting. Yet, there is insufficient current research on the efficacy, regulations, and side effects. More extensive studies are needed on these outlined topics to further extract the methodology and benefit of SARMs for the future .
2. Can SARMs Cause Damage?
Research indicates steroids are becoming increasingly popular amongst immature test subjects . Studies show adolescent subjects are at an increased risk for permanent damage because they are still growing and developing . Further, studies show any anabolic steroid before full maturity can put a subject at risk for :
- Reduced testicular size
- Liver toxicity
- Fluid retention
- Cardiovascular issues
- High blood pressure
Unregulated use of SARMs has also added concerns over permanent damage. A case study found that a test subject used SARMs Ostarine without medical or professional supervision. The previously healthy male subject had signs of :
Multiple panels returned normal results, suggesting that the problem was isolated to a drug-induced injury. The subject required consistent follow-up for the next several weeks to months, and the subject’s liver function prognosis was unclear .
While Ostarine has the potential to have positive tissue-specific functions, this study highlights the importance of clinical trial monitoring. The preliminary research also pinpoints the need for close medical management in subjects before targeting the effects in adolescent subjects .
3. Testosterone and SARMs
- Liver toxicity
- Heart attack
- Reduced testosterone levels
Ongoing SARMs research is needed to determine long-term effects, risks, and benefits. Currently, it states testosterone supplements and boosters have similar risks. They can increase a subject’s chances of cardiovascular events and prostate cancer .
Other complications could include increased acne, testicular shrinkage, or sleep apnea. Combining SARMs and testosterone could stunt growth and normal hormonal levels, especially in young male subjects. The long-term outlook of using both androgen combinations is unknown .
4. Can You research SARMs and Anabolics at <18?
There is not enough research or efficacy on any anabolic steroid or nonsteroidal products for adolescent subjects or subjects of any age .
These should only be used in clinical trials and for research as other effects remain unknown. Combining SARMs and anabolics could result in similar effects as noted above. More Selective Androgen Receptor Modulators, SARMs research is needed for its effects on puberty .
Anabolics for specific cases involving delayed puberty under a doctor’s supervision have been researched as well as for low testosterone levels. Yet, these are medically managed and monitored cases.
Subjects should never perform research on anabolics, including SARMs without being a part of a clinical trial for legally applicable conditions as their negative effects may be magnified or permanent when experienced during puberty.
5. Are SARMs FDA-Approved?
Unlike anabolic steroids, Selective Androgen Receptor Modulators, SARMs are not FDA-approved. The FDA warns that a prescription is required for anabolic androgenic steroids. Clinical development and research studies are still needed before SARMs can go through an FDA approval process .
SARMs are also not approved by the world anti-doping agency.
Where does the research stand?
- Lung cancer
- Alzheimer’s disease
Much of this preliminary research is found in mice, showing improvements in cognition and small cell lung cancer. With ongoing high-quality research, SARMs may hold more benefits than first anticipated .
Update: Frequently Asked Questions about SARMs and Their Role in Research
SARMs, or Selective Androgen Receptor Modulators, have gained attention in recent years due to their potential in enhancing muscle mass and addressing various health conditions .
These compounds have shown promise in a wide range of therapeutic applications, including chronic obstructive pulmonary disease (COPD) and cancer-related muscle wasting. As a result, they have become the subject of extensive preclinical and clinical development programs .
One of the key advantages of SARMs is their ability to selectively target androgen receptors in skeletal muscle without significantly affecting androgenic tissues, such as the prostate .
By displaying tissue-selective activation, SARMs offer the possibility of promoting muscle growth while minimizing the adverse events associated with anabolic androgenic steroids and testosterone supplementation .
This feature makes them a potentially safer alternative for increasing muscle mass in populations such as cancer patients, individuals with chronic diseases, and postmenopausal women .
It is important to note that while SARMs hold great potential, further research is still necessary to fully understand their long-term effects and safety profile.
Rigorous statistical analysis and comprehensive evaluation of adverse events are vital in assessing the overall benefits and risks associated with SARMs as they are still undergoing clinical testing.
Additionally, investigations into the impact of SARMs on prostate-specific antigen (PSA) levels and androgenic signaling pathways are essential to determine their potential prostate effects. With ongoing research and scientific advancements, SARMs may pave the way for novel function-promoting therapies and contribute to improving the quality of life for individuals with various health conditions [2,3,4].
Facilitating SARMs Research
Questions about SARMs are increasing on the internet. Unfortunately, this has led to many misconceptions where more research is needed.
SARMs have many compounds that have tissue-specific functions. As research evolves, breakthroughs could be found for life-altering compounds and treatments.
Are you interested in participating in clinical research with SARMs like Ligandrol, RAD140, and YK11? Quality research starts with a quality product. To get started answering SARMs questions and for the highest-quality SARMs products, check out our website on these products and other chemical compounds.
- Machek, S. B., Cardaci, T. D., Wilburn, D. T., & Willoughby, D. S. (2020). Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review. Steroids, 164, 108753.
- Gao, W., & Dalton, J. T. (2007). Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug discovery today, 12(5-6), 241-248.
- Allan, G. F., Tannenbaum, P., Sbriscia, T., Linton, O., Lai, M. T., Haynes-Johnson, D., … & Lundeen, S. G. (2007). A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine, 32, 41-51.
- Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W. (2019). Selective androgen receptor modulators: current knowledge and clinical applications. Sexual medicine reviews, 7(1), 84-94.
- Bedi, H., Hammond, C., Sanders, D., Yang, H. M., & Yoshida, E. M. (2021). Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG case reports journal, 8(1).
- Hartgens, F., & Kuipers, H. (2004). Effects of androgenic-anabolic steroids in athletes. Sports medicine, 34, 513-554.
- Lee, B. K., Park, B. B., & Bower, R. J. (2022). Selective Androgen Receptor Modulator–Induced Liver Injury in Active Duty Male. Military Medicine.
- Choi, S. M., & Lee, B. M. (2015). Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids. Expert opinion on drug safety, 14(11), 1773-1785.
- Ebner, N., Springer, J., Kalantar-Zadeh, K., Lainscak, M., Doehner, W., Anker, S. D., & Von Haehling, S. (2013). Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas, 75(3), 199-206.